+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - August 2022

  • PDF Icon

    Report

  • 14 Pages
  • August 2022
  • Region: Global
  • GlobalData
  • ID: 5661516
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer looks at the data from clinical trials for vaccines and therapeutics either currently marketed or in the pipeline. The data is assessed, and the different products are compared against each other both clinically and commercially.

This report is an update of the previous COVID-19 Clinical and Commercial analyzer, which analyzes the available data of pipeline and marketed therapeutics and vaccines for COVID-19.

Report deliverables are an interactive Excel-based that has the Analyzer tab, which weights different clinical and commercial contributors per product, the competitive assessment tab, which is a graph representing the products by their clinical and commercial scores, the dashboard tab, which gives details and a SWOT analysis of each product, and the clinical data tab, which lists the key clinical trials and data for the products.

This update includes a weighted view of the impact of the Omicron variant on the products

Scope

  • In depths assessment of the marketed and pipeline products for COVID-19, analyzing the clinical and commercial aspects of the products against one another.
  • This update includes a weighted view of the impact of the Omicron variant on the products

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of marketed and pipeline products and technologies, and by identifying the companies with the most robust pipeline and marketed products.
  • Understand the strengths and weaknesses of pipeline and marketed products, and how they compare against one another.
  • Develop business strategies by understanding the trends shaping and driving the COVID-19 market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global COVID-19 vaccine and therapeutic market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Table of Contents
1.1 Catalyst
1.2 Scope & Methodology
1.3 Clinical and Commercial Analyzer: Therapeutics
1.4 Competitive Assessment: Therapeutics
1.5 Product Dashboard: Therapeutics
1.6 Clinical Data: Therapeutics
1.7 Clinical and Commercial Analyzer: Vaccines
1.8 Competitive Assessment: Vaccines
1.9 Product Dashboard: Vaccines
1.10 Clinical Data: Vaccines
1.11 About the Publisher

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pfizer
  • BioNTech
  • Moderna
  • AstraZeneca
  • Johnson & Johnson
  • Novavax
  • CureVac
  • Sanofi
  • GlaxoSmithKline
  • Arcturus
  • Medicago
  • Valneva
  • Inovio
  • Sinopharm
  • Gamaleya Research Institute
  • Bharat Biotech
  • CanSino Biologics
  • Sinovac Biotech
  • Chongqing Zhifei
  • Clover Biopharmaceuticals
  • Medicago
  • Vaxart
  • Gilead
  • Fujifilm
  • Vir Biotechnology
  • Roche
  • Chugai
  • Eli Lilly
  • Merck
  • Regeneron
  • Celltrion
  • Alexion
  • Synairgen
  • Octapharma
  • CytoDyn
  • Humanigen
  • Abcellera
  • NeuroRx
Relief Therapeutics
  • RedHill
  • Novartis
  • Molecular Partners
  • EUSA Pharma